Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 30OTHER 28NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 2Recurrence 1

Interventions

Dexamethasone 45Bortezomib 21Lenalidomide 19Cyclophosphamide 19daratumumab 16Calcium Dobesilate 13Thalidomide 12Melphalan 11carfilzomib 9Prednisone 7pomalidomide 6Peripheral Blood Stem Cell Transplantation 6Doxorubicin 6Filgrastim 5dexamethasone acetate 4dexamethasone 21-phosphate 4auricularum 4Vincristine 4isatuximab 3Interferon-alpha 3Etoposide 3selinexor 2sargramostim 2ixazomib 2elotuzumab 2cobimetinib 2Steroids 2Radiotherapy 2Microarray Analysis 2Granulocyte Colony-Stimulating Factor 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Multiple Myeloma × elotuzumab × Clear all
NCT05028348 2025-12-04

A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

European Myeloma Network B.V.

Phase 3 Active not recruiting
117 enrolled
Plasma cell

Multiple Myeloma

NCT04150965 2025-02-14

Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

Multiple Myeloma Research Consortium

Phase 1/2 Terminated
14 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡